{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T12:31:45Z","timestamp":1784118705118,"version":"3.55.0"},"reference-count":64,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1111\/j.1524-4725.2012.02435.x","type":"journal-article","created":{"date-parts":[[2012,5,14]],"date-time":"2012-05-14T15:26:20Z","timestamp":1337009180000},"page":"971-984","source":"Crossref","is-referenced-by-count":64,"title":["Advances in the Treatment of Melasma: A Review of the Recent Literature"],"prefix":"10.1097","volume":"38","author":[{"given":"Katharine L. Ball","family":"Arefiev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basil M.","family":"Hantash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-1-20210206","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/978-1-4615-4857-7_72","article-title":"Melasma.","volume":"455","author":"Kauh","year":"1999","journal-title":"Adv Exp Med Biol"},{"key":"R2-1-20210206","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1111\/j.1468-3083.2009.03295.x","article-title":"A global survey of the role of ultraviolet radiation and hormonal influences in the development of melasma.","volume":"23","author":"Ortonne","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R3-1-20210206","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1365-4632.2004.02470.x","article-title":"Prevalence and awareness of melasma during pregnancy.","volume":"45","author":"Moin","year":"2006","journal-title":"Int J Dermatol"},{"key":"R4-1-20210206","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-4362.1988.tb02329.x","article-title":"Melasma in men. A clinical and histologic study.","volume":"27","author":"Vazquez","year":"1988","journal-title":"Int J Dermatol"},{"key":"R5-1-20210206","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/j.1468-3083.2007.02472.x","article-title":"Effect of melasma on quality of life in a sample of women living in southern Brazil.","volume":"22","author":"Freitag","year":"2008","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"Suppl 1","key":"R6-1-20210206","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1365-2133.2006.07590.x","article-title":"Guidelines for clinical trials in melasma. Pigmentation Disorders Academy.","volume":"156","author":"Pandya","year":"2006","journal-title":"Br J Dermatol"},{"key":"R7-1-20210206","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/09546630601028778","article-title":"Melasma and its impact on healthrelated quality of life in Hispanic women.","volume":"18","author":"Pawaskar","year":"2007","journal-title":"J Dermatol Treat"},{"key":"R8-1-20210206","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1046\/j.1365-2133.2003.05419.x","article-title":"Development and validation of a healthrelated quality of life instrument for women with melasma.","volume":"149","author":"Balkrishnan","year":"2003","journal-title":"Br J Dermatol"},{"issue":"Suppl","key":"R9-1-20210206","first-page":"S27","article-title":"Utilizing combination therapy to optimize melasma outcomes.","volume":"5","author":"Rendon","year":"2004","journal-title":"J Drugs Dermatol"},{"key":"R10-1-20210206","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/j.1365-4362.1992.tb02718.x","article-title":"Incidence of skin disease in Cuzco, Peru.","volume":"31","author":"Failmezger","year":"1992","journal-title":"Int J Dermatol"},{"key":"R11-1-20210206","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S0190-9622(81)70071-9","article-title":"Melasma: a clinical, light microscopic, ultrastructural, and immunofluorescence study.","volume":"4","author":"Sanchez","year":"1981","journal-title":"J Am Acad Dermatol"},{"key":"R12-1-20210206","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1046\/j.0007-0963.2001.04556.x","article-title":"Melasma: histopathological characteristics in 56 Korean patients.","volume":"146","author":"Kang","year":"2002","journal-title":"Br J Dermatol"},{"key":"R13-1-20210206","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/j.1365-2133.2006.07179.x","article-title":"The dermal stem cell factor and ckit are overexpressed in melasma.","volume":"154","author":"Kang","year":"2006","journal-title":"Br J Dermatol"},{"key":"R14-1-20210206","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1600-0749.2003.00126.x","article-title":"Autocrine and paracrine regulation of melanocytes in human skin and in pigmentary disorders.","volume":"17","author":"Imokawa","year":"2004","journal-title":"Pigment Cell Res"},{"key":"R15-1-20210206","first-page":"4041","article-title":"Comparison of the responses of human melanocytes with different melanin contents to ultraviolet B irradiation.","volume":"55","author":"Barker","year":"1995","journal-title":"Cancer Res"},{"key":"R16-1-20210206","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/01.dad.0000154419.18653.2e","article-title":"Light microscopic, immunohistochemical, and ultrastructural alterations in patients with melasma.","volume":"27","author":"Grimes","year":"2005","journal-title":"Am J Dermatopathol"},{"key":"R17-1-20210206","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1172\/JCI117224","article-title":"Proopiomelanocortinderived peptides are synthesized and released by human keratinocytes.","volume":"93","author":"Schauer","year":"1994","journal-title":"J Clin Invest"},{"key":"R18-1-20210206","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1046\/j.1365-2133.2002.4513_3.x","article-title":"Increased expression of alphamelanocytestimulating hormone in the lesional skin of melasma.","volume":"146","author":"Im","year":"2002","journal-title":"Br J Dermatol"},{"key":"R19-1-20210206","first-page":"47","article-title":"Activation of the cyclic AMP pathway by alphamelanotropin mediates the response of human melanocytes to ultraviolet B radiation.","volume":"58","author":"Im","year":"1998","journal-title":"Cancer Res"},{"key":"R20-1-20210206","first-page":"463","article-title":"Estrogen receptor expression in melasma: results from facial skin of affected patients.","volume":"7","author":"Lieberman","year":"2008","journal-title":"J Drugs Dermatol"},{"key":"R21-1-20210206","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1001\/jama.1967.03120090043007","article-title":"Melasma induced by oral contraceptive drugs.","volume":"199","author":"Resnik","year":"1967","journal-title":"JAMA"},{"key":"R22-1-20210206","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1046\/j.1365-2133.1998.02537.x","article-title":"Melasma of the arms associated with hormone replacement therapy.","volume":"139","author":"Johnston","year":"1998","journal-title":"Br J Dermatol"},{"key":"R23-1-20210206","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1046\/j.1365-2133.1999.03078.x","article-title":"Melasma of the arms associated with hormone replacement therapy.","volume":"141","author":"Varma","year":"1999","journal-title":"Br J Dermatol"},{"key":"R24-1-20210206","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0960-0760(94)90295-X","article-title":"Effects of estrogens on human melanocytes in vitro.","volume":"49","author":"McLeod","year":"1994","journal-title":"J Steroid Biochem Mol Biol"},{"key":"R25-1-20210206","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/1523-1747.ep12477126","article-title":"Human melanocytes as a target tissue for hormones: in vitro studies with 1 alpha25, dihydroxyvitamin D3, alphamelanocyte stimulating hormone, and betaestradiol.","volume":"91","author":"Ranson","year":"1988","journal-title":"J Invest Dermatol"},{"key":"R26-1-20210206","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/1523-1747.ep12522896","article-title":"Endocrinologic profile of patients with idiopathic melasma.","volume":"81","author":"Perez","year":"1983","journal-title":"J Invest Dermatol"},{"key":"R27-1-20210206","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1346-8138.2000.tb02122.x","article-title":"Melasma in men: a hormonal profile.","volume":"27","author":"Sialy","year":"2000","journal-title":"J Dermatol"},{"key":"R28-1-20210206","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1210\/jcem-61-1-28","article-title":"Association of melasma with thyroid autoimmunity and other thyroidal abnormalities and their relationship to the origin of the melasma.","volume":"61","author":"Lutfi","year":"1985","journal-title":"J Clin Endocrinol Metab"},{"key":"R29-1-20210206","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1001\/archderm.1995.01690240119022","article-title":"Melasma. Etiologic and therapeutic considerations.","volume":"131","author":"Grimes","year":"1995","journal-title":"Arch Dermatol"},{"key":"R30-1-20210206","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/120347540400800204","article-title":"Melasma: a review.","volume":"8","author":"Victor","year":"2004","journal-title":"J Cutan Med Surg"},{"key":"R31-1-20210206","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.jaad.2006.02.009","article-title":"The treatment of melasma: a review of clinical trials.","volume":"55","author":"Gupta","year":"2006","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl 2","key":"R32-1-20210206","doi-asserted-by":"crossref","first-page":"S272","DOI":"10.1016\/j.jaad.2005.12.039","article-title":"Treatment of melasma.","volume":"5","author":"Rendon","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"R33-1-20210206","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1468-3083.2009.03251.x","article-title":"Latin American pigmentary disorders A. Melasma in Latin America: options for therapy and treatment algorithm.","volume":"23","author":"Cestari","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R34-1-20210206","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1473-2165.2007.00321.x","article-title":"Hyperpigmentation and melasma.","volume":"6","author":"Rigopoulos","year":"2007","journal-title":"J Cosmet Dermatol"},{"key":"R35-1-20210206","first-page":"003583","article-title":"Interventions for melasma.","volume":"7","author":"Rajaratnam","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"R37-1-20210206","first-page":"177","article-title":"Communitybased trial of a triplecombination agent for the treatment of facial melasma.","volume":"77","author":"Grimes","year":"2006","journal-title":"Cutis"},{"key":"R38-1-20210206","first-page":"67","article-title":"Efficacy and safety of a new triplecombination agent for the treatment of facial melasma.","volume":"72","author":"Taylor","year":"2003","journal-title":"Cutis"},{"key":"R39-1-20210206","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.jaad.2009.06.067","article-title":"Continuous therapy followed by a maintenance therapy regimen with a triple combination cream for melasma.","volume":"62","author":"Grimes","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"R40-1-20210206","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1473-2165.2007.00288.x","article-title":"A comparison of triple combination cream and hydroquinone 4 cream for the treatment of moderate to severe facial melasma.","volume":"6","author":"Ferreira Cestari","year":"2007","journal-title":"J Cosmet Dermatol"},{"key":"R41-1-20210206","first-page":"697","article-title":"A randomized controlled trial of the efficacy and safety of a fixed triple combination (fluocinolone acetonide 0.01, hydroquinone 4, tretinoin 0.05) compared with hydroquinone 4 cream in Asian patients with moderate to severe melasma.","volume":"159","author":"Chan","year":"2008","journal-title":"Br J Dermatol"},{"key":"R42-1-20210206","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/j.1346-8138.2008.00522.x","article-title":"Efficiency of ellagic acid and arbutin in melasma: a randomized, prospective, openlabel study.","volume":"35","author":"Ertam","year":"2008","journal-title":"J Dermatol"},{"key":"R43-1-20210206","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/iub.143","article-title":"Ellagic acid: characterization as substrate of polyphenol oxidase.","volume":"61","author":"MunozMunoz","year":"2009","journal-title":"IUBMB Life"},{"key":"R44-1-20210206","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1248\/bpb.28.2216","article-title":"Inhibitory effects of 4nbutylresorcinol on tyrosinase activity and melanin synthesis.","volume":"28","author":"Kim","year":"2005","journal-title":"Biol Pharm Bull"},{"key":"R45-1-20210206","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1111\/j.1365-2133.2007.07814.x","article-title":"Evaluation of efficacy and safety of rucinol serum in patients with melasma: a randomized controlled trial.","volume":"156","author":"Khemis","year":"2007","journal-title":"Br J Dermatol"},{"key":"R46-1-20210206","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1346-8138.2010.00787.x","article-title":"Efficacy and safety of liposomeencapsulated 4nbutylresorcinol 0.1 cream for the treatment of melasma: a randomized controlled splitface trial.","volume":"37","author":"Huh","year":"2010","journal-title":"J Dermatol"},{"key":"R47-1-20210206","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/1523-1747.ep12547184","article-title":"Identification of tyrosinase inhibitors in cultures of Pityrosporum.","volume":"71","author":"NazzaroPorro","year":"1978","journal-title":"J Invest Dermatol"},{"key":"R48-1-20210206","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1346-8138.2007.00211.x","article-title":"Efficacy and safety of serial glycolic acid peels and a topical regimen in the treatment of recalcitrant melasma.","volume":"34","author":"Erbil","year":"2007","journal-title":"J Dermatol"},{"key":"R49-1-20210206","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1038\/jid.2009.124","article-title":"Shortsequence oligopeptides with inhibitory activity against mushroom and human tyrosinase.","volume":"129","author":"Abu Ubeid","year":"2009","journal-title":"J Invest Dermatol"},{"key":"R50-1-20210206","first-page":"732","article-title":"A splitface, doubleblind, randomized and placebocontrolled pilot evaluation of a novel oligopeptide for the treatment of recalcitrant melasma.","volume":"8","author":"Hantash","year":"2009","journal-title":"J Drugs Dermatol"},{"key":"R51-1-20210206","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1524-4725.2010.01481.x","article-title":"Glycolic acid peels versus amino fruit acid peels in the treatment of melasma.","volume":"36","author":"Ilknur","year":"2010","journal-title":"Dermatol Surg"},{"key":"R53-1-20210206","first-page":"205","article-title":"Comparison of 30 salicylic acid with Jessners solution for superficial chemical peeling in epidermal melasma.","volume":"18","author":"Ejaz","year":"2008","journal-title":"J Coll Physicians Surg Pak"},{"key":"R54-1-20210206","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.jaad.2009.12.027","article-title":"A prospective, randomized, splitface, controlled trial of salicylic acid peels in the treatment of melasma in Latin American women.","volume":"63","author":"Kodali","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"R55-1-20210206","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1473-2165.2009.00471.x","article-title":"Different therapeutic modalities for treatment of melasma.","volume":"8","author":"Azzam","year":"2009","journal-title":"J Cosmet Dermatol"},{"key":"R56-1-20210206","doi-asserted-by":"crossref","first-page":"041115","DOI":"10.1117\/1.2241745","article-title":"Laserinduced transepidermal elimination of dermal content by fractional photothermolysis.","volume":"11","author":"Hantash","year":"2006","journal-title":"J Biomed Opt"},{"key":"R57-1-20210206","first-page":"315","article-title":"The treatment of melasma with topical creams alone, CO2 fractional ablative resurfacing alone, or a combination of the two: a comparative study.","volume":"9","author":"Trelles","year":"2010","journal-title":"J Drugs Dermatol"},{"key":"R58-1-20210206","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/j.1524-4725.2010.01523.x","article-title":"Lowfluence Qswitched neodymiumdoped yttrium aluminum garnet laser for melasma with pre or posttreatment triple combination cream.","volume":"36","author":"Jeong","year":"2010","journal-title":"Dermatol Surg"},{"key":"R59-1-20210206","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1524-4725.2009.01383.x","article-title":"Lowfluence Qswitched neodymiumdoped yttrium aluminum garnet (1,064 nm) laser for the treatment of facial melasma in Asians.","volume":"36","author":"Wattanakrai","year":"2010","journal-title":"Dermatol Surg"},{"key":"R60-1-20210206","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jaad.2010.01.048","article-title":"Nonablative 1550nm fractional laser therapy versus triple topical therapy for the treatment of melasma: a randomized controlled pilot study.","volume":"64","author":"Kroon","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"R61-1-20210206","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/lsm.20937","article-title":"Nonablative 1,550 nm fractional laser therapy versus triple topical therapy for the treatment of melasma: a randomized controlled splitface study.","volume":"42","author":"Wind","year":"2010","journal-title":"Lasers Surg Med"},{"key":"R62-1-20210206","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/00042728-200104000-00016","article-title":"Intense pulsed light for melanocytic lesions.","volume":"27","author":"Moreno Arias","year":"2001","journal-title":"Dermatol Surg"},{"key":"R63-1-20210206","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1524-4725.2010.01849.x","article-title":"Sequential treatment with triple combination cream and intense pulsed light is more efficacious than sequential treatment with an inactive (control) cream and intense pulsed light in patients with moderate to severe melasma.","volume":"37","author":"Goldman","year":"2011","journal-title":"Dermatol Surg"},{"key":"R64-1-20210206","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/ptr.1085","article-title":"Treatment of melasma with Pycnogenol.","volume":"16","author":"Ni","year":"2002","journal-title":"Phytother Res"},{"key":"R67-1-20210206","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1529-8019.2007.00144.x","article-title":"Skin lightening preparations and the hydroquinone controversy.","volume":"20","author":"Draelos","year":"2007","journal-title":"Dermatol Ther"},{"key":"R68-1-20210206","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.jaad.2007.02.020","article-title":"The safety of hydroquinone: a dermatologists response to the 2006 Federal Register.","volume":"57","author":"Levitt","year":"2007","journal-title":"J Am Acad Dermatol"}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00042728-201207010-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T11:27:06Z","timestamp":1713958026000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00042728-201207010-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":64,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1524-4725.2012.02435.x","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717960739.793467812","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.717960739.793463660","asserted-by":"object"}]},"ISSN":["1076-0512"],"issn-type":[{"value":"1076-0512","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}